Par Pharmaceutical Cos. Inc. (PRX) News

News for Par Pharmaceutical Cos. Inc.  (PRX) 
Sector News | Topic News
$ 36.55   -0.50 (-1.35%) Volume: 186.06 k 4:01 PM EST Feb 10, 2012
After Hours:  $ 36.55 0.00 (0.00%) Volume: 2.32 k 4:34 PM EST Feb 10, 2012
View News From:  
Mon, Feb 06, 2012
12:01 PM Robbins Umeda LLP Announces an Investigation of Par Pharmaceutical Companies, Inc. - Business Wire
Tue, Jan 31, 2012
9:00 AM Par Pharmaceutical Companies to Report Fourth Quarter and Full Year 2011 Results on February 28, 2012 - PR Newswire
Wed, Dec 21, 2011
6:00 AM IntelGenx Announces Development and Commercialization Agreement with Par Pharmaceutical, Inc. - Newsfile
Mon, Dec 05, 2011
9:37 AM Par Pharmaceutical to Host Analyst Day on January 6, 2012 - PR Newswire
Tue, Nov 22, 2011
8:30 AM Par Pharmaceutical Companies Promotes Thomas J. Haughey to President and Paul V. Campanelli to Chief Operating Officer - PR Newswire
Thu, Nov 17, 2011
12:45 PM Par Pharmaceutical Completes Acquisition of Anchen - PR Newswire
Wed, Nov 02, 2011
7:30 AM Par Pharmaceutical Companies Reports Third Quarter 2011 Results - PR Newswire
Mon, Oct 24, 2011
3:34 PM Par Pharmaceutical Begins Shipment of Generic Zyprexa® Zydis® - PR Newswire
Tue, Oct 18, 2011
9:00 AM Par Pharmaceutical Acquires Three Generic Products From Teva Pharmaceuticals - PR Newswire
Fri, Oct 14, 2011
4:15 PM Par Pharmaceutical Files Declaratory Judgment to Protect First Amendment Rights to Disseminate Truthful Information Regarding Megace® ES - PR Newswire
Fri, Oct 07, 2011
9:00 AM Expert's Economic Outlook, Global - Equity Research on Par Pharmaceutical Companies, Inc. and Targacept, Inc. - Marketwire
Mon, Oct 03, 2011
4:15 PM Par Pharmaceutical Companies to Report Third Quarter 2011 Results on November 2, 2011 - PR Newswire
9:00 AM Global Situation & Resulting Influences - Research Report on Akorn, Inc. and Par Pharmaceutical Companies, Inc. - Marketwire
Mon, Aug 22, 2011
9:55 AM The Zacks Analyst Blog Highlights: Par Pharmaceutical Companies, Intellipharmaceutics International, Celgene Corporation, Novartis AG and Elan Corporation plc - PR Newswire